International Flavors & Fragrances 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- IFF reported 3rd quarter revenue of just under $2 billion, up roughly 5% on a comparable currency-neutral basis, with growth across all businesses.
- EBITDA was $403 million, up 6%, and EBITDA margin was 20.8%, up 20 basis points, on a comparable currency-neutral basis.
- Taste sales increased 6% to $687 million and EBITDA rose 7% to $128 million; Scent sales grew 6% to $689 million and EBITDA grew 10% to $139 million.
- Health and Biosciences sales grew 1% to $566 million and EBITDA increased 2% to $139 million; mid-single-digit growth in Food Biosciences and Grain Processing more than offset a decline in Health.
- For the first 9 months of 2026, sales grew 4%, EBITDA rose 7%, adjusted operating EBITDA margin improved 50 basis points, and free cash flow totaled $371 million, up $245 million versus last year.
- Cash flow from operations totaled $820 million, year-to-date CapEx was $449 million, and IFF returned $306 million through dividends and $584 million through share repurchases in the first 9 months of 2026.
- IFF completed a $500 million accelerated share repurchase, repurchasing approximately 5.8 million shares, or approximately 2.3% of shares outstanding, and does not plan additional share repurchases for the 4th quarter 2026.
- At September 30th, cash and cash equivalents totaled $519 million, gross debt was approximately $6.3 billion, and net debt to credit-adjusted EBITDA was 2.75 times.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
At this time, I would like to welcome everyone to the IFF third quarter 2026 earnings conference call. All participants will be in a listen-only mode until the formal question-and-answer portion of the call. To ask a question at that time, please press star one on your telephone keypad. If you would like to remove your name from the queue, please press star two. Participants will be announced by their name and company. In order to give all participants an opportunity to ask their questions, we request a limit of one question per person. I would now like to introduce Michael Bender, Head of Investor Relations. You may begin. Thank you.
Good morning, good afternoon, and good evening, everyone. Welcome to IFF's third quarter 2026 earnings conference call. Yesterday afternoon, we issued a press release announcing our financial results. A copy of the release can be found on our IR website at ir.iff.com. Please note that this call is being recorded live and will be available for replay. During the call, we will be making forward-looking statements about the company's performance and business outlook. These statements are based on how we see things today and contain elements of uncertainty. For additional information concerning factors that can cause actual results to differ materially, please refer to our cautionary statement and risk factors contained in our 10-K and press release, both of which can be found on our website. Today's presentation will include non-GAAP financial measures, which exclude those items that we believe affect comparability.
A reconciliation of these non-GAAP financial measures to their respective GAAP measures is set forth in the press release. Also, please note that all sales and EBITDA growth numbers that we will be speaking to on the call are all on a comparable currency-neutral basis unless otherwise noted. Given the announced divestiture of Food Ingredients, we discuss the results and guidance on a continuing operations basis unless otherwise noted. Our P&L financials are presented on a continuing operations basis, while cash flow, net debt to credit-adjusted EBITDA leverage, and CapEx are presented on a total company basis, which includes both continuing operations and discontinued operations. With me on the call today is our CEO, Erik Fyrwald, and our CFO, Michael DeVeau. We will begin with prepared remarks and then take questions at the end. With that, I would now like to turn the call over to Erik.
Thanks, Mike, and hello, everyone. Thank you for joining us today. IFF delivered strong results in the third quarter, with year-over-year growth across every business segment. We drove increased revenue and improved profitability across all divisions, with particularly strong performances in Taste and Scent. Our progress through the first nine months of 2026 is evidence that our portfolio transformation is better positioning IFF for strong growth and sustained healthy margins. This solid year-to-date performance gives us the confidence to raise the lower end of our full-year guidance ranges, even when factoring in the ongoing macroeconomic uncertainty the world is facing. In short, our team is executing on our strategy, and we have momentum delivering value for our customers and for our shareholders. I will start today's call by briefly summarizing our results and providing an update on our strategic progress and continued portfolio transformation efforts.
I'll then turn the call over to Michael DeVeau, who will provide more details on the third quarter results, segment performance, and our outlook for the remainder of 2026. Turning to slide six. I'm encouraged by IFF's strong performance over the first nine months of 2026. Sales grew 4% and EBITDA rose 7%, delivering a 50 basis points improvement in adjusted operating EBITDA margin, all on a currency-neutral basis. In the third quarter, we delivered both top and bottom line growth across all segments. Our solid third quarter was led by mid-single-digit sales growth contributions from Taste and Scent, and modest sales growth in Health & Biosciences, driven by contributions from new wins and from existing business.
For the first nine months of 2026, free cash flow totaled $371 million, and this represents a gain of $245 million versus last year, supported by improved net working capital, an area of focus for us as we came into 2026. We also recently completed our accelerated share repurchase plan, returning $500 million to shareholders, underscoring our confidence in the direction of the business and our strategic plan. At the same time, we continue to invest in our highest growth opportunities, which positions us well for the years ahead. Given the strength of our volume growth and our strong year-to-date performance, we are raising the low end of both full-year guidance ranges.
We are controlling what we can control and delivering the financial commitments we set out earlier in the year, a testament to the resilience of our business amid changing macroeconomic conditions and their impact on input costs, currencies, interest rates, and consumer demand. Our updated outlook incorporates some near-term profitability softness in the fourth quarter, particularly in Health & Biosciences, where we are seeing higher costs and continued market softness. At the same time, the team remains fully focused on strengthening the business through reinvestment. We are also working with customers on pricing and driving productivity to mitigate higher costs, positioning us well going forward and giving us confidence that we can deliver financial results within our guidance range. At IFF, we are delivering for our customers, advancing our strategy, and building a more focused, innovative, and stronger company.
I want to recognize that this would not be possible without the dedication of our global team. Our results demonstrate the impact of our volume growth initiatives and productivity, while our disciplined approach to capital allocation continues to create value for our shareholders, and we remain focused on building on this progress and executing with discipline through the year end and beyond. Now, moving to slide seven. I want to step back from the quarter and update you on our progress against the growth-oriented simplification strategy we introduced in early 2023. Throughout the year, we have focused on keeping this strategy at the center of our decision-making, continuing to strengthen our position as a global industry leader while sharpening our portfolio focus on high-value, consumer-centric ingredients markets. As we shared last quarter, we agreed to sell the Food Ingredients business to CVC Capital Partners for about $4.3 billion.
The separation is progressing well, and we remain on track to close the transaction by the end of the first half of 2027. As the separation advances, our focus remains with CVC on achieving the planned closing timeline. We will continue to balance speed with rigor, ensuring that the transaction readiness and ongoing business priorities move forward together. While a separation of this scale and complexity requires significant focus and effort, we have aligned the team with incentives to reinforce disciplined execution, maintain momentum, and move with appropriate speed. We also completed the sale of Soy Crush, Concentrates, and Lecithin, or SCL, and agreed to divest the non-strategic botanical extracts, vitamins and minerals, and food enhancement businesses, which we expect to close by year-end. With Food Ingredients and SCL now reported as discontinued operations, our continuing operations are Taste, Scent, and Health & Biosciences.
Our portfolio now reflects our commitment to a sharper, high-quality portfolio with stronger growth and margin potential, aligned to the long-term megatrends that shape demand across our industries. In the wake of this transformation, we are utilizing our capital in the most efficient and effective ways possible to drive our growth potential. We announced a $2.5 billion share repurchase authorization, including a $500 million accelerated share repurchase that we have already completed. At the same time, we are investing in profitable growth opportunities while doubling down on the innovative creativity and technology solutions expertise our customers expect from IFF. Recent milestones include opening a vanilla innovation center in Madagascar, launching a home care application lab in Brazil, and expanding our fermentation-based enzyme capabilities in Argentina.
We will also launch a new state-of-the-art Scent creative center in Mumbai in December, and together, they show IFF's distinctive blend of science and creativity at work. With a simpler operating model and strengthening manufacturing network, we will be better positioned to accelerate innovation, improve execution, enhance free cash flow conversion, and deliver a stronger long-term growth and margin profile. Our shared naturals and biosciences capabilities power growth opportunities across Taste, Scent, and Health & Biosciences, and the progress we are delivering confirms that our strategy is working and positions IFF to create sustainable value. However, there is more work ahead as we look to continue this journey. Now, with that, I'll pass the call to Mike for a closer look at this quarter's consolidated results.
Mike. Thank you, Erik, and thanks everyone for joining us today.
On slide eight, we take a closer look at our Q3 consolidated results. IFF generated revenues of just under $2 billion in the third quarter, up roughly 5% on a comparable currency-neutral basis, with growth across all businesses. This strong performance was led by mid-single-digit growth in Scent and Taste and a low single-digit performance in Health & Biosciences. Growth was primarily driven by volume, with contributions from both new wins and growth on existing business. EBITDA totaled $403 million for the quarter, up 6%, driven by volume contributions, and EBITDA margin was 20.8%, up 20 basis points, both of which are on a comparable currency-neutral basis.
These results show the progress we are making in executing our volume and productivity-focused strategy, and importantly, the combination of sales growth and margin expansion demonstrates our ability to translate volume gains into improved earnings. On slide nine, I'll provide a closer look at the performance of each business segment. In Taste, sales increased 6% to $687 million, with growth across all regions once again. Greater Asia led the way with double-digit growth, followed by Latin America, which was up high single digits, EMEA up mid-single digits, and North America up low single digits. Looking at profitability in Taste, the segment delivered EBITDA of $128 million, a 7% increase from the year-ago period, driven by volume growth. In Scent, sales grew a strong 6% to $689 million.
Third quarter performance was driven by a high single-digit increase in Consumer Fragrances and mid-single-digit performances in Fragrance Ingredients and Fine Fragrance, which was up against a strong double-digit year-ago comparable. Scent profitability was also strong, with EBITDA growing 10% to $139 million. Volume growth was the primary driver of the increase in profitability. Lastly, Health & Biosciences grew 1% to $566 million. Mid-single-digit growth in Food Biosciences and Grain Processing more than offset a decline in health, where the market conditions are challenged. As Erik noted, the team continues to work on the health turnaround and remain focused on the factors within our control. This includes sharpening our execution, advancing self-help initiatives, and investing selectively to strengthen the business to position the health business for improved performance as market recovers.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
18 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
